ECSP13012448A - Nuevas aminopirazoloquinazolinas. - Google Patents
Nuevas aminopirazoloquinazolinas.Info
- Publication number
- ECSP13012448A ECSP13012448A ECSP13012448A ECSP13012448A EC SP13012448 A ECSP13012448 A EC SP13012448A EC SP13012448 A ECSP13012448 A EC SP13012448A EC SP13012448 A ECSP13012448 A EC SP13012448A
- Authority
- EC
- Ecuador
- Prior art keywords
- aminopirazoloquinazolinas
- new
- compounds
- medicines
- radicals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención comprende compuestos de la fórmula general (I)en donde los radicales R1 hasta R3 y X están definidos como en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que se caracterizan por una proliferación celular excesiva o anómala, a preparaciones farmacéuticas que contienen tales compuestos y a su empleo como medicamentos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170683 | 2010-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13012448A true ECSP13012448A (es) | 2013-03-28 |
Family
ID=43037625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13012448 ECSP13012448A (es) | 2010-07-23 | 2013-02-19 | Nuevas aminopirazoloquinazolinas. |
Country Status (22)
Country | Link |
---|---|
US (1) | US8735386B2 (es) |
EP (1) | EP2595987B1 (es) |
JP (1) | JP5991974B2 (es) |
KR (1) | KR20130132394A (es) |
CN (1) | CN103097388A (es) |
AP (1) | AP2012006640A0 (es) |
AR (1) | AR082850A1 (es) |
AU (1) | AU2011281504A1 (es) |
BR (1) | BR112013000107A2 (es) |
CA (1) | CA2803467A1 (es) |
CL (1) | CL2012003745A1 (es) |
CO (1) | CO6670575A2 (es) |
EA (1) | EA201201661A1 (es) |
EC (1) | ECSP13012448A (es) |
GE (1) | GEP20156289B (es) |
MA (1) | MA34389B1 (es) |
MX (1) | MX2013000821A (es) |
PE (1) | PE20131143A1 (es) |
SG (1) | SG187548A1 (es) |
TW (1) | TW201217380A (es) |
UY (1) | UY33526A (es) |
WO (1) | WO2012010704A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9150578B2 (en) * | 2012-01-23 | 2015-10-06 | Boehringer Ingelheim International Gmbh | 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
CN110669047A (zh) * | 2013-11-15 | 2020-01-10 | 昂克希尔迪克斯有限公司 | 用于治疗癌症的化合物、其组合物及应用方法 |
MX2021001096A (es) | 2015-01-30 | 2023-01-17 | Oncoceutics Inc | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. |
US10414769B2 (en) | 2015-05-13 | 2019-09-17 | Boehringer Ingelheim International Gmbh | 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors |
CN113264935B (zh) * | 2016-11-11 | 2022-09-20 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物及其中间体和医药上的用途 |
US11597725B2 (en) * | 2017-05-26 | 2023-03-07 | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. | URAT1 inhibitor for promoting uric acid excretion |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
EP3786161A4 (en) * | 2018-04-24 | 2021-05-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | CDK4 / 6 INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC OF THEM AND ASSOCIATED USE |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
CA3128200A1 (en) * | 2019-01-30 | 2020-08-06 | Yale University | Compounds, compositions, and methods for treating fibrosis |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
CN113518775A (zh) * | 2019-03-07 | 2021-10-19 | 生物技术公司 | 用于制备经取代的咪唑并喹啉的方法 |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
US20220175819A1 (en) * | 2019-04-19 | 2022-06-09 | Fount Bio, Inc. | Delivery and retention of active agents within the skin |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
AR119765A1 (es) | 2019-08-14 | 2022-01-12 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
JP2023529867A (ja) | 2020-06-05 | 2023-07-12 | キネート バイオファーマ インク. | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
WO2022166725A1 (zh) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 5,6-二氢噻吩并[3,4-h]喹唑啉类化合物 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2233003A1 (en) * | 1995-10-02 | 1997-04-10 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as 5ht2c-receptor antagonists |
RS20050944A (en) | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en active Application Filing
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Application Discontinuation
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO6670575A2 (es) | 2013-05-15 |
PE20131143A1 (es) | 2013-10-23 |
AR082850A1 (es) | 2013-01-16 |
US20120238542A1 (en) | 2012-09-20 |
MX2013000821A (es) | 2013-05-30 |
BR112013000107A2 (pt) | 2016-05-17 |
GEP20156289B (en) | 2015-05-25 |
MA34389B1 (fr) | 2013-07-03 |
CN103097388A (zh) | 2013-05-08 |
AU2011281504A1 (en) | 2013-01-10 |
EA201201661A1 (ru) | 2013-07-30 |
US8735386B2 (en) | 2014-05-27 |
JP2013532652A (ja) | 2013-08-19 |
AP2012006640A0 (en) | 2012-12-31 |
JP5991974B2 (ja) | 2016-09-14 |
EP2595987B1 (en) | 2018-04-18 |
CA2803467A1 (en) | 2012-01-26 |
CL2012003745A1 (es) | 2013-05-31 |
UY33526A (es) | 2012-02-29 |
WO2012010704A1 (en) | 2012-01-26 |
KR20130132394A (ko) | 2013-12-04 |
SG187548A1 (en) | 2013-03-28 |
EP2595987A1 (en) | 2013-05-29 |
TW201217380A (en) | 2012-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012448A (es) | Nuevas aminopirazoloquinazolinas. | |
CY1119387T1 (el) | Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου | |
UY32259A (es) | Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones | |
UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
UY33199A (es) | 5-alquinil-pirimidinas. | |
UY32916A (es) | Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones | |
UY33890A (es) | Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa | |
ECSP15008851A (es) | Compuestos heteroaromáticos como inhibidores de btk | |
UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
ECSP11011558A (es) | Nuevos compuestos químicos. | |
UY31198A1 (es) | Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones. | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
ECSP14013215A (es) | Compuestos novedosos | |
UY33349A (es) | Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos | |
CO6331434A2 (es) | Nuevos compuestos | |
ECSP11011454A (es) | 5-alquinil-piridinas | |
ECSP12012110A (es) | 5-alquinil-pirimidinas | |
ECSP11011464A (es) | Tia-triaza-ciclopentazulenos | |
TN2013000012A1 (en) | New aminopyrazoloquinazolines | |
ECSP12012115A (es) | 5-alquinil-pirimidinas | |
UY33816A (es) | ?nuevas triazolilfenil sulfonamidas como inhibidores de serina/treonina cinasa?. |